GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandinavian ChemoTech AB (OSTO:CMOTEC B) » Definitions » EV-to-Revenue

Scandinavian ChemoTech AB (OSTO:CMOTEC B) EV-to-Revenue : 5.71 (As of Jul. 07, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Scandinavian ChemoTech AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Scandinavian ChemoTech AB's enterprise value is kr43.90 Mil. Scandinavian ChemoTech AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was kr7.69 Mil. Therefore, Scandinavian ChemoTech AB's EV-to-Revenue for today is 5.71.

The historical rank and industry rank for Scandinavian ChemoTech AB's EV-to-Revenue or its related term are showing as below:

OSTO:CMOTEC B' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.01   Med: 101.43   Max: 6681.03
Current: 5.71

During the past 9 years, the highest EV-to-Revenue of Scandinavian ChemoTech AB was 6681.03. The lowest was 2.01. And the median was 101.43.

OSTO:CMOTEC B's EV-to-Revenue is ranked better than
58.97% of 992 companies
in the Biotechnology industry
Industry Median: 8.065 vs OSTO:CMOTEC B: 5.71

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-07), Scandinavian ChemoTech AB's stock price is kr1.92. Scandinavian ChemoTech AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was kr0.35. Therefore, Scandinavian ChemoTech AB's PS Ratio for today is 5.47.


Scandinavian ChemoTech AB EV-to-Revenue Historical Data

The historical data trend for Scandinavian ChemoTech AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandinavian ChemoTech AB EV-to-Revenue Chart

Scandinavian ChemoTech AB Annual Data
Trend Jun15 Jun16 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 634.61 3,041.40 110.88 16.77 6.22

Scandinavian ChemoTech AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.72 7.76 10.08 6.22 3.30

Competitive Comparison of Scandinavian ChemoTech AB's EV-to-Revenue

For the Biotechnology subindustry, Scandinavian ChemoTech AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scandinavian ChemoTech AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scandinavian ChemoTech AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Scandinavian ChemoTech AB's EV-to-Revenue falls into.


;
;

Scandinavian ChemoTech AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Scandinavian ChemoTech AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=43.897/7.693
=5.71

Scandinavian ChemoTech AB's current Enterprise Value is kr43.90 Mil.
Scandinavian ChemoTech AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandinavian ChemoTech AB  (OSTO:CMOTEC B) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Scandinavian ChemoTech AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=1.92/0.351
=5.47

Scandinavian ChemoTech AB's share price for today is kr1.92.
Scandinavian ChemoTech AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scandinavian ChemoTech AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Scandinavian ChemoTech AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Scandinavian ChemoTech AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 1, Medicon Village, Lund, SWE, 223 63
Scandinavian ChemoTech AB is a Sweden based clinical development company. It is engaged in research on pain management and therapy for prostate cancer.

Scandinavian ChemoTech AB Headlines

No Headlines